Navigation Links
Added Drug Aids MS Treatment
Date:2/16/2010

Multi-center study shows daclizumab reduces disease activity when added to interferon beta

TUESDAY, Feb. 16 (HealthDay News) -- Adding the drug daclizumab to standard treatment with interferon beta may reduce multiple sclerosis disease activity more than interferon beta alone, a new study reports.

Previous non-randomized studies found that daclizumab -- a humanized monoclonal antibody -- reduced MS disease activity.

This new phase 2 study at 51 centers in the United States, Canada, Germany, Italy and Spain included 230 patients with active relapsing MS who were taking interferon beta. They were randomly selected to also receive either high-dose daclizumab (2 milligrams/kilogram every two weeks), low-dose daclizumab (1 milligram/kilogram every four weeks) or an inactive placebo. The combined treatments continued for 24 weeks.

MRI scans of the patients' brains were taken every four weeks between weeks 8 and 24 of the study in order to determine the number of new or enlarged gadolinium contrast-enhancing lesions, which indicate MS disease activity.

By the end of the study, the adjusted mean number of new or enlarged gadolinium contrast-enhancing lesions was 1.32 in the high-dose group (75 patients), 3.58 in the low-dose group (78 patients) and 4.75 in the placebo group (77 patients).

Levels of CD56bright natural killer cells were seven to eight times higher in patients taking daclizumab than in those taking the placebo.

"This study provides confirmatory data that daclizumab treatment causes an expansion of CD56bright natural killer cells and adds support to the theory that expansion of CD56bright natural killer cells might mediate some of the effects of daclizumab on reducing multiple sclerosis lesion activity. In addition to the results of previous trials of daclizumab in multiple sclerosis, several lines of evidence have suggested a potential immunoregulatory function for CD56bright na
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Corals added to IUCN Red List of Threatened Species for first time
2. Halozyme Therapeutics Added to Nasdaq Biotech Index
3. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. An Event Added to Celebrate and Empower North Carolina Women
5. Blood pressure drug may have added benefit
6. VA Has Added 20 New Vet Centers
7. Turner Investment Partners Added to AHA Diversified Equity Fund
8. Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRALs(R) Live On-air Charity Special Night of Too Many Stars: An Overbooked Concert for Autism Education Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET
9. IPC The Hospitalist Company Added to Russell 2000 Index
10. Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus
11. Avastin Added to Chemo Helps Women With Advanced Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
(Date:2/27/2015)... A new study published in the Journal ... cycle on a regular basis and prostate cancer. While cycling ... the more hours per week a man spends cycling, the ... an increased importance on prostate cancer screening methods. , “This ... closely at patents’ risk factors for developing prostate cancer,” says ...
(Date:2/27/2015)... 27, 2015 On March 2-4, ... the National Cancer Institute (NCI) will co-host the ... National Institutes of Health (NIH), in Bethesda, Maryland. ... dedicated to medical professionals and scientists who specialize ... the general public, including patients, their families, and ...
(Date:2/27/2015)... Pipette.com announces their limited time pricing on ... valid until the end of March 2015. The Vortex-Genie ... mixer that allows for absolute control and true vortexing. ... is headquartered in Bohemia, New York. Scientific Industries manufactures ... other rockers, incubators, and hybridization ovens which are made ...
(Date:2/27/2015)... NC (PRWEB) February 27, 2015 The ... leading cancer research funding organizations, is excited to announce ... ways to participate and many long-standing partnerships highlight The ... and focus on expanding ways for all to get ... donations to cutting-edge cancer research, The V Foundation has ...
Breaking Medicine News(10 mins):Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3
... 20 Pressure BioSciences, Inc. (Nasdaq: PBIO ... on various corporate activities, including (1) the receipt of ... from the National Institutes of Health ("NIH"), (2) a ... School of Public Health on the significant advantages ...
... Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly eFoodSafety.com, Inc. (OTC ... conference call held on March 19, 2009 at 4:30 p.m. ... at 7:30 PM ET to March 26, 2009 at 11:59 ... 1-201-612-7415 (international). To listen to the replay, please provide ...
... SANTA MONICA, Calif., March 20 Cord Blood America, ... cord blood stem cell storage company, has selected Somerville ... West Los Angeles as public relations counsel for Cord ... and CEO of Cord Blood America. The agency ...
... indicates that some aspects of peoples, cognitive skills such ... and detect relationships peak at about the age of ... 27. , "This research suggests that some aspects of age-related ... in their 20s and 30s," said Timothy Salthouse, a University ...
... 20 , - On Average a ... and Poland Claim Worsening Quality of Sleep,Thanks to the Economy(1) , ... Making the Admission, Compared,to 17% of the UK(1) , ... Problems Sleeping,Over the Last 12 Months, but Only 19% of These ...
... the Society for Human Resource Management reports that ... sexual harassment policy, a recent University of Missouri ... effective in preventing workplace harassment. Researchers in the ... way individuals define and explain their understanding of ...
Cached Medicine News:Health News:Pressure BioSciences, Inc. Provides Corporate Update 2Health News:Pressure BioSciences, Inc. Provides Corporate Update 3Health News:Pressure BioSciences, Inc. Provides Corporate Update 4Health News:Pressure BioSciences, Inc. Provides Corporate Update 5Health News:Nuvilex Provides Conference Call Replay Information 2Health News:Cord Blood America, Inc. Appoints Somerville Associates, Public Relations Counsel 2Health News:Cognitive decline begins in late 20s, study suggests 2Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 2Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 3Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 4Health News:New Survey Highlights the Significant Impact of the Economic Downturn on Europe's Sleep 5Health News:Perceptions of similar language may prevent understanding of sexual harassment policies 2
(Date:2/27/2015)... LONDON , February 27, 2015 ... - new study showing you trends, R&D progress, and ... medicine heading? What are the commercial prospects for ... shows you potential revenues and other trends to 2025, ... ,s report lets you assess regenerative medicine : ...
(Date:2/27/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the fourth quarter and full year ended December 31, ... for PTC. We are now a growing commercial-stage biopharma ... the rare disease space," stated Stuart W. Peltz, Ph.D., ... to bring the first treatment for Duchenne muscular dystrophy ...
(Date:2/27/2015)... Feb. 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... today that it acquired Bionik Laboratories, Inc., a ... the sale to qualified accredited investors of units consisting ... proceeds of approximately $6.2 million. Shares of the Company,s ... OTC Markets under the symbol "DWTPD" until FINRA,s approval ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: